Illumina secures CMS reimbursement for TruSight(TM) Oncology Comprehensive, expanding access to precision oncology
MWN-AI** Summary
Illumina, Inc. has secured reimbursement approval from the Centers for Medicare and Medicaid Services (CMS) for its TruSight™ Oncology (TSO) Comprehensive test, a significant stride in advancing precision oncology within the United States healthcare system. Starting January 1, 2026, the test will be reimbursed at a rate of $2,989.55 per test under the Clinical Laboratory Fee Schedule, utilizing the Proprietary Laboratory Analysis (PLA) code 0543U. This decision is expected to enhance the accessibility of comprehensive genomic profiling (CGP) for patients, a critical component in modern oncology care.
John Fox, MD, Senior Director of Market Access and Government Affairs at Illumina, emphasized that this reimbursement removes barriers that have previously limited the adoption of CGP. TSO Comprehensive evaluates over 500 genes, providing clinicians with actionable insights that significantly inform treatment decisions, thereby promoting better patient outcomes. With this reimbursement, laboratories across the spectrum, including academic medical centers and regional reference labs, can offer CGP in-house and deliver timely genomic insights directly to patients.
The decision highlights the increasing demand for genomic testing across the healthcare landscape, which opens up opportunities for improved healthcare and patient quality of life. Illumina has indicated that in the previous fiscal year, 60% of its sequencing consumables revenue stemmed from clinical customers, reflecting the growing importance of genomic testing in medical diagnostics.
TSO Comprehensive not only aids in identifying various cancer biomarkers but is also approved as a companion diagnostic for certain treatments, enhancing its clinical utility. Overall, this development reinforces Illumina’s role in shaping the future of precision medicine and facilitating improved cancer care through genomic insights.
MWN-AI** Analysis
Illumina's recent announcement regarding the Centers for Medicare and Medicaid Services (CMS) reimbursement for its TruSight™ Oncology Comprehensive (TSO) test represents a significant development in the precision oncology sector. With a set reimbursement rate of $2,989.55 per test, this decision is poised to enhance accessibility and adoption of comprehensive genomic profiling (CGP), a critical advancement for cancer treatment methodologies.
The TSO Comprehensive test enables clinicians to analyze over 500 genes, facilitating the identification of relevant biomarkers that can drive targeted therapies. By securing Medicare reimbursement, Illumina effectively eliminates a major barrier that has historically hindered the widespread adoption of CGP in clinical settings. This change could potentially lead to a surge in demand for the test among healthcare providers, particularly as precision medicine continues to gain traction in oncology.
From a market perspective, Illumina is well-positioned for growth. The company has reported that around 60% of its sequencing consumables revenues in 2025 were sourced from clinical customers, highlighting a robust demand for their genomic products. Investors should take note of the strategic advantage this reimbursement provides by potentially increasing laboratory adoption rates and driving revenue growth.
Furthermore, as more healthcare facilities adopt CGP, Illumina's TSO Comprehensive could be regarded as an essential tool in oncology treatment regimens, increasing the likelihood of patient referrals for genetic testing. This trend will likely bolster Illumina's competitive edge within the genomic profiling market while fostering collaborations with pharmaceutical companies focusing on personalized medicine.
In summary, investors should view Illumina's reimbursement acquisition as a pivotal moment for the company and the precision oncology landscape, supporting a positive long-term growth outlook in align with increasing healthcare demands and advancements in personalized therapies.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
The FDA-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test, helping to advance adoption in the US healthcare system
SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that reimbursement has been granted for its FDA-approved in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test. The reimbursement decision from the Centers for Medicare and Medicaid Services (CMS) will expand access to comprehensive genomic profiling (CGP) and the growing role of personalized genomics in oncology care.
"This decision helps removes barriers that have limited adoption of comprehensive genomic profiling for patients, empowering more healthcare providers to deliver precision oncology insights that will improve outcomes," said John Fox, MD, senior director, Market Access and Government Affairs at Illumina.
TSO Comprehensive gives clinicians the ability to simultaneously assess hundreds of genes—including relevant cancer biomarkers—to inform treatment decisions. With reimbursement now in place, more laboratories will be able to bring CGP in-house and deliver clinically actionable results to their patients, closer to the point of care.
TSO Comprehensive enables laboratories of all sizes to deliver FDA-approved, clinically valuable genomic insights that are easy to access and implement. This promotes broader access to precision oncology diagnostics across academic medical centers, healthcare networks, hospitals, and regional reference laboratories.
Effective January 1, 2026, TSO Comprehensive is reimbursed under the Clinical Laboratory Fee Schedule at a rate of $2,989.55 using Proprietary Laboratory Analysis (PLA) code 0543U, which establishes a clear and predictable reimbursement pathway for all Medicare beneficiaries.
Advancing clinical genomics across the healthcare ecosystem
Clinical demand for genomic testing is growing at every level of the health care ecosystem. With that demand comes opportunity for better health care and improved quality of life by advancing access to and adoption of tests like TSO Comprehensive.
Earlier this month, Illumina reported preliminary unaudited financials for the fourth quarter and fiscal year 2025, which highlighted clinical markets as a key driver of growth. Roughly 60% of the company's sequencing consumables revenue was driven by clinical customers last year.
About TruSight Oncology Comprehensive
TruSight Oncology Comprehensive is a single FDA-approved test that interrogates more than 500 genes to profile a patient's solid tumor, helping increase the likelihood of identifying immuno-oncology or other clinically actionable biomarkers that can guide targeted therapy selection or clinical trial enrollment.
TSO Comprehensive is approved as a companion diagnostic (CDx) to identify adult and pediatric patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusions and may benefit from treatment with Bayer's VITRAKVI® (larotrectinib). The test is also approved to identify adult patients with locally advanced or metastatic rearranged-during-transfection (RET) fusion-positive non-small-cell lung cancer (NSCLC) who may benefit from treatment with Lilly's RETEVMO® (selpercatinib).
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) customer uptake of, and satisfaction with, new and existing products and services; and (ii) our ability to obtain or maintain regulatory approval for our products from government agencies and reimbursement from payors, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
SOURCE Illumina, Inc.
FAQ**
How might the CMS reimbursement for TruSight™ Oncology Comprehensive impact the market share of Illumina Inc. ILMN in the oncology testing segment over the next few years?
What strategies does Illumina Inc. ILMN plan to implement to ensure that healthcare providers are aware of the reimbursement decision for the TruSight™ Oncology Comprehensive test?
Given the reimbursement rate of $2,989.55 per test, how does Illumina Inc. ILMN expect this will influence the financial performance of the company in the upcoming quarters?
What potential risks does Illumina Inc. ILMN foresee in customer uptake of the TruSight™ Oncology Comprehensive test following the CMS reimbursement announcement?
**MWN-AI FAQ is based on asking OpenAI questions about Illumina Inc. (NASDAQ: ILMN).
NASDAQ: ILMN
ILMN Trading
-1.46% G/L:
$120.935 Last:
604,601 Volume:
$122 Open:
